Stay Informed on Key Developments

Investor News and Updates

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

231 - 240of 392 News

May 22, 2020

Not intended for U.S. and UK Media

Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancer

May 19, 2020

Nine internationally recognized experts join Sustainability Council

Independent external council to advise Bayer’s Board of Management on consistent implementation of its sustainability targets

May 11, 2020

Not intended for U.S. and UK Media

Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program

April 28, 2020

CEO Werner Baumann at the Bayer AG Annual Stockholders’ Meeting:

"We’re active in the right businesses"

April 27, 2020

First quarter of 2020:

Bayer: Good start to 2020 - activities marked by COVID-19

April 21, 2020

Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments

March 30, 2020

Not intended for U.S. and UK Media

Nubeqa™ (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer

March 29, 2020

Not intended for U.S. and UK Media - New study results add to solid evidence for the efficacy and safety of Rivaroxaban in the prevention of venous thromboembolism:

Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery

March 28, 2020

Not intended for U.S. and UK Media - Data from Phase III VICTORIA study presented at American College of Cardiology’s 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC)

Vericiguat significantly reduced the risk of the composite primary endpoint of cardiovascular death or heart failure hospitalization

March 28, 2020

Not intended for U.S. and UK Media - Data from Phase III VOYAGER PAD study published in The New England Journal of Medicine and presented during the American College of Cardiology’s 69th Annual Scientific Session together with World Congress of Cardiology

Xarelto™ 2.5 mg plus aspirin significantly lowered the combined risk of limb ischemia and major cardiovascular events in patients with symptomatic peripheral artery disease post revascularization

Inform Yourself on Special Topics

Investor News and Updates

Control Weeds, Not Farming

Everything You Need to Know About Glyphosate

Managing Glyphosate Litigation

Managing and Mitigating PCB Litigation Risk